BEAM MEXC RealStocks
Own real BEAM shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-12 20:32:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Beam Therapeutics Inc. (BEAM) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $24.20, with a market capitalization of $2.60B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $20.23 to $38.26. This page covers its latest market performance, valuation, price trends and company information.
$2.60B | |
$25.06 | |
$25.63 | |
$24.19 | |
$25.81 | |
944.00K | |
1.89M | |
-- | |
$38.26 | |
$20.23 | |
-- | |
-- |
Beam Therapeutics Inc. (BEAM) is currently trading at $24.20 as of 2026-11-12 20:16:39, down 5.81% ($1.50) from the previous close of $25.81
During today's regular trading session, BEAM has traded between $24.19 and $25.63, with a trading volume of 944.00K shares. The current price is near the lower end of today's range.
Over the past seven days, Beam Therapeutics Inc. (BEAM) moved from $26.33 to $24.20, representing a decline of 8.09% ($2.13).
The stock traded between $23.60 and $28.00 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.96 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 22.0%
BEAM is currently trading at $24.20, placing it 22.0% of the way from its 52-week low of $20.23 to its 52-week high of $38.26. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 540 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Beam Therapeutics Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Beam Therapeutics Inc. (BEAM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to BEAM, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between BEAM shares and USD.
BEAM Shares to USD
1.00 BEAM shares = 24.2 USD
Calculations are estimates based on the latest available price and are for reference only.